| P50 | author | QiZhi Zheng | Q58453252 |
| | Tsuyoshi Iwata | Q93041453 |
| | Srinivasan Yegnasubramanian | Q95939090 |
| | Carlise Bethel | Q117270276 |
| | Angelo M De Marzo | Q56417148 |
| P2093 | author name string | Cheryl M Koh | |
| P2860 | cites work | ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer | Q21091136 |
| | An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB | Q24299235 |
| | An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression | Q24313269 |
| | A microRNA expression signature of human solid tumors defines cancer gene targets | Q24541455 |
| | Widespread microRNA repression by Myc contributes to tumorigenesis | Q24647067 |
| | MicroRNA expression, survival, and response to interferon in liver cancer | Q24647241 |
| | Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 |
| | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 |
| | EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells | Q24672969 |
| | Global mapping of c-Myc binding sites and target gene networks in human B cells | Q24675083 |
| | An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets | Q24792966 |
| | c-Myc-regulated microRNAs modulate E2F1 expression | Q27861046 |
| | Control of developmental regulators by Polycomb in human embryonic stem cells | Q28235841 |
| | Micro-RNA profiling in kidney and bladder cancers | Q28247306 |
| | MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis | Q28269041 |
| | MYC stimulates EZH2 expression by repression of its negative regulator miR-26a | Q28291303 |
| | Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features | Q79393350 |
| | Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma | Q28304953 |
| | Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions | Q29614512 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism | Q29617213 |
| | Polycomb silencers control cell fate, development and cancer | Q29619697 |
| | MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells | Q33535955 |
| | Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines | Q33766326 |
| | Circulating microRNAs (miRNA) in serum of patients with prostate cancer | Q34182161 |
| | EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer | Q34268216 |
| | Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer | Q34803786 |
| | Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene | Q34805348 |
| | The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? | Q35008935 |
| | EZH2 is essential for glioblastoma cancer stem cell maintenance | Q35014308 |
| | Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis | Q35207795 |
| | The c-Myc target gene network | Q36564217 |
| | Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements | Q36929833 |
| | Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer | Q37198891 |
| | MicroRNA profiling and head and neck cancer | Q37208449 |
| | Roles of the EZH2 histone methyltransferase in cancer epigenetics | Q37250591 |
| | Reflecting on 25 years with MYC. | Q37333643 |
| | Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line | Q37478998 |
| | Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. | Q38259629 |
| | Widespread deregulation of microRNA expression in human prostate cancer. | Q38297946 |
| | E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. | Q38304702 |
| | MicroRNA target prediction by expression analysis of host genes | Q38511523 |
| | MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta | Q39703169 |
| | A polycomb repression signature in metastatic prostate cancer predicts cancer outcome | Q40050697 |
| | MicroRNA expression profiling in prostate cancer | Q40110318 |
| | The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer | Q40297700 |
| | Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. | Q40339620 |
| | ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification | Q41489983 |
| | Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth | Q43262197 |
| | EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast | Q44864337 |
| | Myc-driven murine prostate cancer shares molecular features with human prostate tumors | Q45049671 |
| | Activated p53 suppresses the histone methyltransferase EZH2 gene | Q47314793 |
| | Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. | Q53332426 |
| | Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. | Q54392904 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 669-683 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms | |
| P478 | volume | 2 | |